HEMATOPOIETIC CELL TRANSPLANTATION FOR JUVENILE MYELOMONOCYTIC LEUKEMIA AND OTHER MYELOPROLIFERATIVE NEOPLASMS
Authors:
- Neysimelia Costa VillelaNVNeysimelia Costa Villela
- Anita Frisanco OliveiraAOAnita Frisanco Oliveira
- Rafaela de Souza FerreiraRFRafaela de Souza Ferreira
- Gustavo ZamperliniGZGustavo Zamperlini
- Andréia Cristina Fortes BassaniABAndréia Cristina Fortes Bassani
- Mariana Bohns MichalowskiMariana Bohns Michalowski
- Maria Lúcia de Martino LeeMLMaria Lúcia de Martino Lee
Open Access
- 22 January 2025
- journal article
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Abstract
Juvenile myelomonocytic leukemia (JMML) is a rare and distinctive hematologic neoplasm affecting infants and younger children. Hyperactivation of the RAS signaling pathway is a central initiating event in JMML, which also delineates its various genetic and clinical subtypes. While a small percentage of children may achieve spontaneous clinical remission, allogeneic hematopoietic cell transplantation (HCT) remains the only possible cure for most JMML patients. In this article, we reviewed the indications of HCT in JMML. Other myeloproliferative diseases, such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis, are extremely rare in pediatrics and are briefly discussed.Keywords
This publication has 44 references indexed in Scilit:
- Polycythemia vera and essential thrombocythemia in children, still a challenge for pediatriciansEuropean Journal of Pediatrics, 2025
- Myeloproliferative neoplasms: young patients, current data and future considerationsAnnals of Hematology, 2024
- The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemiaVirchows Archiv, 2022
- Short-term efficacy of decitabine-based therapy in JMML: a retrospective study from a single center in ChinaInternational Journal of Hematology, 2022
- Myeloproliferative Neoplasms in Children, Adolescents, and Young AdultsCurrent Hematologic Malignancy Reports, 2020
- Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemiaPediatric Blood & Cancer, 2019
- Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group studyPediatric Blood & Cancer, 2018
- Myeloproliferative neoplasms in childrenJournal of Hematopathology, 2015
- Outcomes of immunological interventions for mixed chimerism following allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemiaPediatric Blood & Cancer, 2012
- Non‐hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: A retrospective analysis and definition of response criteriaPediatric Blood & Cancer, 2006